Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P220002/S010

TOPS System

Premia Spine, Ltd. · Decision date Oct 29, 2025

FDA DECISIONP220002/S010

What did the FDA decide?

FDA records P220002/S010 as a supplement to PMA P220002, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Oct 29, 2025.

FDA approval order statement

introduction of a new plug sorting jig, adjustment to the plug cutting and insertion machine, and minor dimensional changes to the plug and top plate components to and improve sealing performance at the Premia Spine Ltd, Ramat Poleg, Netanya, Isreal and TAV Medical Ltd, Israel facilities
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Orthopedic
Decision date
Oct 29, 2025
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P220002/S010
Regulatory pathway
PMA supplement
Product code
QWK
Decision code
OK30
Decision date
Oct 29, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Prosthesis, posterior spinal elements.

Product code
QWK
FDA device class
3

For the original device and its historical approval scope, see PMA P220002. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P220002/S010 received

    Application receipt date recorded by FDA.

  2. P220002/S010 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P220002. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P220002

Product / regulatory recordCompanyPathwayDecision dateSource
Premia Spine, Ltd.PMA approvalJun 15, 2023FDA
TOPS SystemP220002/S009
Premia Spine, Ltd.PMA supplementMay 29, 2026FDA
TOPS SystemP220002/S011
Premia Spine, Ltd.PMA supplementSep 9, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Premia Spine, Ltd.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
7 Giborey Israel St., Ramat Poleg, Netanya, 4250407

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records